Abstract
BACKGROUND/OBJECTIVES: Nocardia seriolae and Aeromonas veronii are two important pathogens that can affect a wide range of fish species and cause substantial economic losses. However, a vaccine that simultaneously protects fish from these two bacterial infections is not yet available. METHODS: Three formalin-inactivated whole-cell vaccines prepared from N. seriolae and A. veronii (Monovalent Av, Monovalent Ns and Bivalent Av-Ns) were generated, and their efficacy was evaluated through a range of tests. The immune-related gene expression in the spleen and head kidney, enzyme activity, and specific antibody levels in serum were also detected. RESULTS: All groups of vaccinated fish exhibited increased serum enzymatic activity compared with control fish, which peaked at week 3 after vaccination; in particular, that of the Bivalent Av-Ns group increased remarkably. The expression of immune-related genes in the spleen, head, and kidneys increased after immunization and were significantly enhanced (p < 0.05) in the bivalent vaccine group. Specific antibodies were produced at the 1st wpv, peaked at the 4th to the 5th wpv, and then decreased at the 6th wpv in all vaccinated groups. The Monovalent Av and Monovalent Ns against A. veronii and N. seriolae showed 56.67% and 22.22% RPS, respectively. Moreover, Bivalent Av-Ns offered 33.33% and 76.67% RPS for single infection with N. seriolae or A. veronii, as well as providing 44.44% RPS for dual infection with combined N. seriolae and A. veronii. CONCLUSIONS: Our findings indicate that the administration of the A. veronii and N. seriolae bivalent vaccine can protect largemouth bass from both bacterial infections.